News and Announcements

On January 11, 2022, the Centers for Medicare & Medicaid Services (CMS) decided to limit its coverage of Aduhelm only to those individuals enrolled in randomized clinical trials conducted in a hospital-based outpatient setting.

Read how the Mesulam Center has navigated 2021, including online conferences and the approval of a controversial drug called aducanumab.

For people who have received a diagnosis of Alzheimer’s or dementia, there is a lot of uncertainty about what the future holds. A partnership between the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease and the Lookingglass Theatre Company sought to lean into that uncertainty.

The Mesulam Center was awarded a $20 million grant from the National Institute on Aging (NIA) to establish an international multi-center SuperAging consortium with locations across the United States and in Canada.

Professor of Psychiatry and Behavioral Sciences at Northwestern School of Medicine, Sandra Weintraub, PhD, discusses Alzheimer’s and what research has found on keeping mentally active.

A biomarker in the brain predicts future cognitive decline in patients with the language form of Alzheimer’s disease (AD), reports a new Northwestern Medicine study.

Eric Williams noticed he was having trouble with finding words as he was writing a novel. Read about Eric's diagnosis of Primary Progressive Aphasia and how he got involved in research.

Ken and Barbara Stevenson share their experience with the Communication Bridge study, a speech language therapy telehealth program.

Casey Benzaken, a second-year dual degree MD/MPH student, is studying the attitudes towards flu vaccines of Northwestern University undergraduates.

The Food and Drug Administration’s approval of the first new drug treatment for Alzheimer’s disease in nearly 20 years has drawn mixed reactions from the medical field nationwide.

“Aducanumab, it is an antibody which recognizes amyloid, which is a substance that accumulates in the brain in Alzheimer’s disease,” said Dr. Marsel Mesulam, director of the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, Northwestern Medicine. 

Earlier today the FDA approved aducanumab (trade name ADUHELM) for use in Alzheimer’s disease. This is a historic milestone, but is met with some controversy.

Ian Grant, MD, shares his expertise as a behavioral neurologist on the PBS Health Channel answering questions from community members about diet and how to prevent dementia.

More than 350 participants attended the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease’s virtual PPA Conference, which featured keynote speakers and group support sessions focused on Primary Progressive Aphasia.

A new Northwestern Medicine study showed cognitive SuperAgers have resistance to the development of fibrous tangles in a brain region related to memory and which are known to be markers of Alzheimer's disease.